MaxCyte, Inc. (MXCT) は上場企業です ヘルスケア セクターの Medical - Devices 業界で事業展開. 本社所在地は Rockville, MD, アメリカ. 現CEOは Maher Masoud.
MXCT を有する IPO日 2021-07-30, 114 名の正社員, に上場 NASDAQ Global Select, 時価総額 $90.32M.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
